

③ *The **ACME** Laboratories Ltd.*  
**First Quarter Un Audited Financial Statements**  
For the period ended 30 September 2023

**The ACME Laboratories Limited**  
**Statement of Financial Position (Un-Audited)**  
As at 30 September 2023

		<b>Amount in Taka</b>	
<b>ASSETS</b>	<b>NOTES</b>	<b>As at 30-09-2023</b>	<b>As at 30-06-2023</b>
<b>Non-Current Assets :</b>		<b>29,713,017,728</b>	<b>29,274,155,747</b>
Property, Plant and Equipment	3	29,589,807,743	29,143,106,373
Right-of-Use Assets		91,530,157	99,533,397
Investment in Securities		31,679,828	31,515,977
<b>Current Assets:</b>		<b>22,741,085,341</b>	<b>21,135,865,863</b>
Inventories	4	7,334,969,434	6,894,247,309
Trade Receivable	5	2,736,197,037	2,705,071,780
Other Receivable		19,935,475	19,887,785
Advance, Deposits & Pre-Payments	6	3,107,436,569	2,988,468,855
Advance Income Tax		3,849,039,162	3,682,324,080
Material In Transit		3,407,479,173	3,340,043,272
Term Deposit		51,101,899	50,446,100
Cash and Cash Equivalents	7	2,234,926,592	1,455,376,682
<b>TOTAL ASSETS</b>		<b>52,454,103,069</b>	<b>50,410,021,610</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Shareholders' Equity :</b>		<b>23,953,972,674</b>	<b>23,295,116,896</b>
Share Capital	8	2,116,017,000	2,116,017,000
Share Premium		5,127,599,728	5,127,599,728
Revaluation Surplus		5,005,899,067	5,017,449,088
Gain/(Loss) on Marketable Securities (Unrealized)		5,093,859	4,809,707
Tax Holiday Reserve		179,464,241	179,464,241
Retained Earnings		11,519,898,779	10,849,777,132
<b>Non Current Liabilities:</b>		<b>8,397,834,897</b>	<b>8,161,492,917</b>
Long Term Loan- Net off Current Maturity		6,366,322,623	6,167,983,247
Long Term Lease Liability		58,067,880	62,292,535
Provision For Gratuity		1,112,271,501	1,028,075,307
Deferred Tax Liability		861,172,893	903,141,828
<b>Current Liabilities:</b>		<b>20,102,295,498</b>	<b>18,953,411,797</b>
Loans & Overdrafts		13,193,437,604	12,523,296,751
Current Maturity of Long Term Loans		2,203,409,753	2,053,979,923
Trade Payable		520,956,578	490,891,189
Provision for Income Tax		3,475,239,089	3,255,425,419
Current Lease Liability		20,994,033	21,855,169
Liability for Expenses and Others		684,194,499	601,458,127
Dividend Payable	18	4,063,942	6,505,219
Unclaimed Dividend Account		-	-
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>52,454,103,069</b>	<b>50,410,021,610</b>
<b>Net Asset Value Per Share (NAVPS)</b>	9	<b>113.20</b>	<b>110.09</b>

Sd/-  
Md. Arshadul Kabir FCA  
Company Secretary (Acting)

Sd/-  
Kazi Mohammed Badruddin FCMA, FCA  
ED & CFO

Sd/-  
Jahanara Mizan Sinha  
Deputy Managing Director

Sd/-  
Mizanur Rahman Sinha  
Managing Director

Sd/-  
Nagina Afzal Sinha  
Chairman

**The ACME Laboratories Limited**  
**Statement of Profit or Loss and Other Comprehensive Income (Un-Audited)**  
For the period ended 30 September 2023

PARTICULARS	Notes	Amount in Taka	
		July'23 to September'23	July'22 to September'22
Revenue		7,920,009,490	6,587,866,228
Less: Cost of Goods Sold	11	4,695,174,660	3,973,188,348
<b>Gross Profit/(Loss)</b>		<b>3,224,834,830</b>	<b>2,614,677,880</b>
Add: Other Income/ (Loss)		(108,980,524)	(8,779,815)
		<b>3,115,854,306</b>	<b>2,605,898,065</b>
Less: Selling, Marketing and Distribution Expenses	12	1,391,165,838	1,140,060,971
		<b>1,724,688,468</b>	<b>1,465,837,094</b>
Less: Administrative Expenses	13	267,722,610	240,256,413
		<b>1,456,965,858</b>	<b>1,225,580,681</b>
Less: Financial Expenses		578,602,364	379,394,278
<b>Profit Before Contribution to WPPF and WWF</b>		<b>878,363,494</b>	<b>846,186,403</b>
Less: Contribution to WPPF and WWF		41,826,833	40,294,591
<b>Net Profit Before Tax</b>		<b>836,536,661</b>	<b>805,891,812</b>
Less: Current Tax Expenses		219,813,670	184,000,814
Less: Deferred Tax (Income)/Expenses		(41,848,635)	2,086,684
<b>Net Profit After Tax</b>		<b>658,571,626</b>	<b>619,804,314</b>
<b>Other Comprehensive Income</b>			
Gain/(Loss) on Marketable Securities (Unrealized)		163,851	(1,473,030)
<b>Total Comprehensive Income for the period</b>		<b>658,735,477</b>	<b>618,331,284</b>
<b>Earnings Per Share (on the Equity share of Tk. 10 each)</b>	15	<b>3.11</b>	<b>2.93</b>

Sd/-  
Md. Arshadul Kabir FCA  
Company Secretary (Acting)

Sd/-  
Kazi Mohammed Badruddin FCMA, FCA  
ED & CFO

Sd/-  
Jahanara Mizan Sinha  
Deputy Managing Director

Sd/-  
Mizanur Rahman Sinha  
Managing Director

Sd/-  
Nagina Afzal Sinha  
Chairman

**The ACME Laboratories Limited**

**Statement of Changes in Equity (Un-Audited)**

For the period ended 30 September 2023

(Amount in Taka)

Particulars	Share Capital	Share Premium	Revaluation Surplus	Gain/(loss) on Marketable Securities (Unrealized)	Tax Holiday Reserve	Retained Earnings	Total
Balance as at July 01, 2023	2,116,017,000	5,127,599,728	5,017,449,088	4,809,707	179,464,241	10,849,777,132	23,295,116,896
Net Profit after Tax for the period ended 30 September 2023	-	-	-	-	-	658,571,626	658,571,626
Gain/(loss) on Marketable Securities (Unrealized)	-	-	-	163,851	-	-	163,851
Adjustment for Depreciation on Revaluation Surplus & Others	-	-	(11,550,021)	-	-	11,550,021	-
Deferred Tax on Unrealized Gain/Losses on Investment in Securities	-	-	-	120,301	-	-	120,301
<b>Balance as at 30 September 2023</b>	<b>2,116,017,000</b>	<b>5,127,599,728</b>	<b>5,005,899,067</b>	<b>5,093,859</b>	<b>179,464,241</b>	<b>11,519,898,779</b>	<b>23,953,972,674</b>
<b>Balance as at 30 September 2022</b>	<b>2,116,017,000</b>	<b>5,127,599,728</b>	<b>5,124,018,352</b>	<b>4,714,156</b>	<b>179,464,241</b>	<b>9,756,779,645</b>	<b>22,308,593,122</b>

Sd/-  
Md. Arshadul Kabir FCA  
Company Secretary (Acting)

Sd/-  
Kazi Mohammed Badruddin FCMA, FCA  
ED & CFO

Sd/-  
Jahanara Mizan Sinha  
Deputy Managing Director

Sd/-  
Mizanur Rahman Sinha  
Managing Director

Sd/-  
Nagina Afzal Sinha  
Chairman

# The ACME Laboratories Limited

## Statement of Cash Flows (Un-Audited)

For the period ended 30 September 2023

### PARTICULARS

		Amount in Taka	
	Notes	July'23 to September'23	July'22 to September'22
<b>Cash Flows From Operating Activities:</b>			
Collection from Sales and others		7,779,809,396	6,569,604,129
Payment to Suppliers & Others		(6,407,364,081)	(5,546,921,405)
Payment to WPPF and WWF		(6,747,150)	(9,766,707)
Cash generated from operation		1,365,698,165	1,012,916,017
Financial Expenses		(578,602,364)	(378,895,175)
Income Tax Paid		(166,715,082)	(101,374,010)
<b>A. Net Cash Generated From Operating Activities</b>		<b>620,380,719</b>	<b>532,646,832</b>
<b>Cash Flows From Investing Activities:</b>			
Acquisition of Property, Plant & Equipments		(850,604,625)	(958,971,235)
Term Deposit		(655,799)	(507,439)
Sale of Property, Plant and Equipment (Motor Vehicles)		-	-
Dividend received from Investment in Marketable Securities		46,623	330,558
<b>B. Net Cash Used in Investing Activities</b>		<b>(851,213,801)</b>	<b>(959,148,116)</b>
<b>Cash Flows From Financing Activities:</b>			
Dividend Paid		(2,441,277)	(329,560)
Principal Portion payment of Lease Liability		(5,085,791)	(6,253,620)
Net Increase / (Decrease) in Loans and Overdrafts		670,140,853	771,933,204
Net Increase / (Decrease) in Long Term Borrowings		347,769,206	(58,706,594)
<b>C. Net Cash Generated/(Used) From Financing Activities</b>		<b>1,010,382,991</b>	<b>706,643,430</b>
Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)		779,549,910	280,142,146
Cash and Cash Equivalents at the Opening		1,455,376,682	1,238,908,488
<b>Cash and Cash Equivalents at the Closing</b>		<b>2,234,926,592</b>	<b>1,519,050,634</b>
<b>Net Operating Cash Flow Per Equity Share (NOCFPS)</b>	16	<b>2.93</b>	<b>2.52</b>

Sd/-  
Md. Arshadul Kabir FCA  
Company Secretary (Acting)

Sd/-  
Kazi Mohammed Badruddin FCMA, FCA  
ED & CFO

Sd/-  
Jahanara Mizan Sinha  
Deputy Managing Director

Sd/-  
Mizanur Rahman Sinha  
Managing Director

Sd/-  
Nagina Afzal Sinha  
Chairman

## The ACME Laboratories Limited

### Notes to the Financial Statements (Un Audited)

As at & for the period ended 30 September 2023

#### 1 Reporting Entity

The ACME Laboratories Ltd. was founded in the year 1954 as a Proprietorship Firm and it was converted into a Private Limited Company on 17th March 1976 vide registration no. C-4745/163 of 1975-76 under the Companies Act-1913. Further, it was converted into a public limited company on 30th November 2011.

#### 2 Basis of Preparation of Financial Statements

These interim financial statements should be read in conjunction with the Annual Financial Statements for the Year ended 30 June 2022, as they provide an update of previously reported information.

These financial statements have been prepared in accordance with Framework, applicable International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs), Companies Act 1994, Bangladesh Securities and Exchange Rules 1987 and other relevant laws and regulations applicable in Bangladesh. The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Previous period's figures have been regrouped/reclassified wherever considered necessary to confirm to current Period's presentation. Figures have been rounded off to the nearest taka, as the currency represented in these financial statements.

3 Property Plant and Equipment	Amount in Taka	
	As at 30-09-2023	As at 30-06-2023
Opening Balance	39,450,188,902	34,629,559,933
Add: Addition (Net off Adjustment) during the Period	826,025,674	4,820,628,969
Less: Accumulated Depreciation (Net off Adjustment)	10,686,406,833	10,307,082,529
Carrying Value	<u>29,589,807,743</u>	<u>29,143,106,373</u>

## The ACME Laboratories Limited

### Notes to the Financial Statements (Un Audited)

As at & for the period ended 30 September 2023

		Amount in Taka	
		As at 30-09-2023	As at 30-06-2023
<b>4 Inventories</b>			
This consists of as follows:			
Raw Materials		3,225,481,568	2,966,921,878
Packing Materials		1,268,722,148	1,148,007,252
Work-in-Process		866,312,308	863,045,385
Finished Goods		1,395,843,567	1,384,387,903
Printing & Stationery		24,091,162	20,523,057
Spare, Accessories & Others		554,518,681	511,361,834
<b>Total</b>		<b>7,334,969,434</b>	<b>6,894,247,309</b>
<b>5 Trade Receivable</b>			
Domestic		2,418,426,420	2,372,163,928
Exports		307,814,628	322,039,413
		2,726,241,048	2,694,203,341
Foreign exchange Unrealized Gain		9,955,989	10,868,439
		<b>2,736,197,037</b>	<b>2,705,071,780</b>
<b>6 Advances, Deposits and Prepayment</b>			
Advances		2,309,705,628	2,224,430,638
Deposit		781,429,138	748,431,527
Prepayments		16,301,803	15,606,690
		<b>3,107,436,569</b>	<b>2,988,468,855</b>
<b>7 Cash and Cash Equivalents</b>			
This is made up as follows :			
Cash in Hand		743,255,674	736,393,037
Cash at Bank		1,490,956,448	718,306,033
Cash at BO Account		714,470	677,612
		<b>2,234,926,592</b>	<b>1,455,376,682</b>

## The ACME Laboratories Limited

### Notes to the Financial Statements (Un Audited)

As at & for the period ended 30 September 2023

		Amount in Taka	
		As at 30-09-2023	As at 30-06-2023
<b>8 Share Capital :</b>			
This is arrived at as follows :			
a) <b>Authorized Capital : Tk 5,000,000,000</b>			
500,000,000 Ordinary share of Tk. 10 each		5,000,000,000	5,000,000,000
b) <b>Issued, Subscribed and Paid - up Capital:</b>			
211,601,700 Ordinary Shares @ Tk. 10 each		2,116,017,000	2,116,017,000
		<b>2,116,017,000</b>	<b>2,116,017,000</b>
c) <b>Movement in Number of Ordinary Shares is as under:</b>			
Opening Balance		211,601,700	211,601,700
Add: Issued during the Period		-	-
Closing Balance		211,601,700	211,601,700
<b>9 Calculation of Net Asset Value (NAV) per ordinary share of Tk. 10 each:</b>			
A Total Equity of the Company		23,953,972,674	23,295,116,896
B Total Number of outstanding ordinary share at the end of the period		211,601,700	211,601,700
C Net Asset Value per Ordinary Share (A/B) rounded of upto two decimal places		<b>113.20</b>	<b>110.09</b>

#### 10 History of allotment of Shares by the Company:

Date of Allotment	Particulars of allotment	Number of ordinary shares allotted	Face Value (Tk)	Amount of Share Capital(Tk.)
17.03.1976	First (Subscription to the Memorandum and Articles of Association at the time of Incorporation)	600	10	6,000
16.05.1976	Second	29,500	10	295,000
10.08.1989	Third	300,000	10	3,000,000
29.11.2006	Fourth	9,669,900	10	96,699,000
05.05.2011	Fifth	106,000,000	10	1,060,000,000
20.05.2013	Sixth	39,631,100	10	396,311,000
26.11.2013	Seventh	5,970,600	10	59,706,000
15.05.2016	Eighth	50,000,000	10	500,000,000
		<b>211,601,700</b>		<b>2,116,017,000</b>



## The ACME Laboratories Limited

### Notes to the Financial Statements (Un Audited)

As at & for the period ended 30 September 2023

		Amount in Taka	
		July 23 to September 23	July 22 to September 22
<b>11 Cost of Goods Sold</b>			
Material Consumption during the period		3,540,393,103	3,065,149,292
Factory Overhead		1,166,237,221	922,173,794
<b>Cost of Production</b>		<b>4,706,630,324</b>	<b>3,987,323,086</b>
Purchase of Finished Goods		-	-
Opening Stock of Finished Goods		1,384,387,903	1,450,565,230
<b>Finished Goods Available</b>		<b>6,091,018,227</b>	<b>5,437,888,316</b>
Closing Stock of Finished Goods		(1,395,843,567)	(1,464,699,968)
<b>Cost of Goods Sold</b>		<b>4,695,174,660</b>	<b>3,973,188,348</b>
<b>12 Selling, Marketing and Distribution Expenses</b>			
Salary, Daily Wages and Other Allowances		973,070,953	796,512,293
Depreciation and others		418,094,885	343,548,678
		<b>1,391,165,838</b>	<b>1,140,060,971</b>
<b>13 Administrative Expenses</b>			
Salary, Daily Wages and Other Allowances		148,975,099	126,304,029
Depreciation and others		118,747,511	113,952,384
		<b>267,722,610</b>	<b>240,256,413</b>
<b>14 Reconciliation of Effective Tax Rate</b>			
Net Profit before Tax		<b>836,536,661</b>	<b>805,891,812</b>
Current Tax Expenses		219,813,670	184,000,814
Deferred Tax Expenses/(Income)		(41,848,635)	2,086,684
		<b>177,965,035</b>	<b>186,087,498</b>
<b>Effective Tax Rate</b>		<b>21.27%</b>	<b>23.09%</b>
<b>15 Basic/Diluted Earning Per Share (EPS):</b>			
Net Profit After Tax		658,571,626	619,804,314
Weighted average number of shares outstanding during the period		211,601,700	211,601,700
<b>Basic Earnings Per Share</b>		<b>3.11</b>	<b>2.93</b>
<b>16 Net Operating Cash Flows Per Share:</b>			
Net cash generated from operating activities		620,380,719	532,646,832
Weighted average number of shares outstanding during the period		211,601,700	211,601,700
<b>Net Operating Cash Flows Per Share</b>		<b>2.93</b>	<b>2.52</b>

## The ACME Laboratories Limited

### Notes to the Financial Statements (Un Audited)

As at & for the period ended 30 September 2023

#### 17 Reconciliation of Net Income or Net Profit with Cash Flows from Operating Activities-Indirect Method

	July 23 to September 23	July 22 to September 22
Net Profit after Tax	658,571,626	619,804,314
Add: Non Cash Items	345,330,422	355,566,986
Less: Net Increase/Decrease in Current Asset	800,434,818	711,439,796
Add: Net Increase/Decrease in Current Liabilities	458,882,424	266,775,947
Add: Deferred Tax Liability (Created during the period)	(41,968,935)	1,939,381
<b>Net cash generated from operating activities-Direct Method</b>	<b><u>620,380,719</u></b>	<b><u>532,646,832</u></b>

#### 18 Dividend Payable

As per BSEC Directive no.BSEC/CMRRCD/2021-386/03 dated 14th January, 2021 Dividend payable not more than 03 years are as follows:

S.L	Financial Year	Dividend	% of Dividend	No. of BO	Date of AGM	Dividend Payable (Tk.)
1	2019-2020	Cash	25%	1,525	10.12.2020	1,041,400
2	2020-2021	Cash	25%	1,282	26.12.2021	1,612,846
3	2021-2022	Cash	30%	1,204	20.12.2022	1,409,696
<b>Dividend Payable as at 30 September 2023</b>						<b><u>4,063,942</u></b>

Sd/-  
Md. Arshadul Kabir FCA  
Company Secretary (Acting)

Sd/-  
Kazi Mohammed Badruddin FCMA, FCA  
ED & CFO

Sd/-  
Jahanara Mizan Sinha  
Deputy Managing Director

Sd/-  
Mizanur Rahman Sinha  
Managing Director

Sd/-  
Nagina Afzal Sinha  
Chairman